Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

A man accused of planning to use spray paint and superglue to vandalise Boris Johnson's wedding party venue will face trial ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

While sentencing a Sarnia man to two years in jail for trafficking crystal meth, the judge noted the drug doesn’t kill people ...

Phil Johnson started about four months ago as chief commercial officer at Evidation. He sat down on the sidelines of JP ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Tech entrepreneur and longevity advocate Bryan Johnson has discontinued his use of rapamycin, a controversial anti-ageing ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

drug prices, and what’s ahead for Johnson & Johnson. This interview has been condensed and edited for clarity. You've had some structural changes and spun out the consumer business. Has that ...